TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33757598

Group type: EXPERIMENTAL
Intervention: Worsening diet quality during the pandemic
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Weight gain during the pandemic
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Isolation during the pandemic
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Completing the survey in Hebrew
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Pre-pandemic diet quality
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: GAD-7 score
Number of subjects: 1895
Study: 33757602

Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness-based group intervention
Number of subjects: 0
Study: 33757717

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 33757788

Group type: EXPERIMENTAL
Intervention: Adherent patients (≥80% drug intake)
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Non-adherent patients (<80% drug intake)
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Patients with ≥9 co-medications
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Post-event adherence rates
Number of subjects: 18113
Study: 33757915

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 200
Study: 33757952

Group type: EXPERIMENTAL
Intervention: Exposure data during pregnancy (questionnaire data, physical examination, biospecimens, medical records, objective environmental data)
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Follow-up every 2 years
Number of subjects: 9193
Study: 33757987

Group type: EXPERIMENTAL
Intervention: Combination of CDK4/6 inhibitor palbociclib, immune checkpoint inhibitor pembrolizumab, and aromatase inhibitor letrozole (palbo+pembro+AI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune checkpoint inhibitor pembrolizumab and aromatase inhibitor letrozole (pembro+AI)
Number of subjects: 0
Study: 33758395

Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LUS assessment at 2 hours
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Early LUS assessment (first 20-30 minutes)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Presence of white lung appearance for 2 hours
Number of subjects: 71
Study: 33758508

Group type: EXPERIMENTAL
Intervention: Normal body weight and moderate coffee consumption (NW/MCC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Normal body weight and heavy coffee consumption (NW/HCC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Overweight and moderate coffee consumption (OW/MCC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Overweight and heavy coffee consumption (OW/HCC)
Number of subjects: 122
Study: 33758521

Group type: EXPERIMENTAL
Intervention: Anterior vertebral body tethering (VBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal fusion
Number of subjects: 0
Study: 33758568

Group type: EXPERIMENTAL
Intervention: Ostomy Adjustment Scale (OAS)
Number of subjects: 302
Study: 33758790

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: %Fat
Number of subjects: 0
Study: 33759264

Group type: EXPERIMENTAL
Intervention: Polysomnography measures of sleep obtained the night preceding surgery
Number of subjects: 16
Study: 33759792

Group type: EXPERIMENTAL
Intervention: MyChoices app
Number of subjects: 11
Study: 33759794

Group type: EXPERIMENTAL
Intervention: Virtual reality headset with eye-tracking device
Number of subjects: 15
Study: 33760701

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33761491

Group type: EXPERIMENTAL
Intervention: bulk-density sCT mimicking the current MRI-linac workflow
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: deep learning-generated sCT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: bulk-density levels
Number of subjects: 10
Study: 33761760

Group type: EXPERIMENTAL
Intervention: Deficiency of MMP1a (Matrix Metalloprotease 1a)
Number of subjects: 0
Study: 33761887

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Beliefs about medications
Number of subjects: 186
Study: 33761902

Group type: EXPERIMENTAL
Intervention: H-HOPE intervention (Massage+ and four participatory guidance sessions)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Implementation of H-HOPE as standard of care
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sustaining H-HOPE
Number of subjects: 5
Study: 33761922

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaire for irAE detection
Number of subjects: 104

Group type: COMPARATOR
Intervention: Clinician-reported irAE
Number of subjects: 104
Study: 33761928

Group type: EXPERIMENTAL
Intervention: aripiprazole lauroxil (AL)
Number of subjects: 291
Study: 33761975

Group type: EXPERIMENTAL
Intervention: Body composition assessment including fat-free mass (FFM), fat mass (FM), and basal metabolic rate (BMR)
Number of subjects: 363
Study: 33761995

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 1430
Study: 33762016

Group type: EXPERIMENTAL
Intervention: Mindfulness training with biofeedback device (n = 18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mindfulness-only control group (n = 21)
Number of subjects: 39
Study: 33762023

Group type: EXPERIMENTAL
Intervention: Collaborative chronic care model (CCM) implementation facilitation after 12 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Collaborative chronic care model (CCM) implementation facilitation
Number of subjects: 58
Study: 33762025

Group type: EXPERIMENTAL
Intervention: Beta-lactam therapeutic drug monitoring (TDM) implementation phases (not yet implemented, partially implemented, fully implemented)
Number of subjects: 30
Study: 33762226

Group type: EXPERIMENTAL
Intervention: Balanced energy-protein (BEP) supplement and iron/folic acid (IFA) tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iron/folic acid (IFA) tablets only
Number of subjects: 100
Study: 33762228

Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 949

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 949
Study: 33762230

Group type: EXPERIMENTAL
Intervention: Prehospital telemedicine system implementation
Number of subjects: 26262
Study: 33762234

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention including physical and laboratory assessment, individualised CV risk assessment, education, treatment recommendations, prescription adaptation, regular communication with treating physician(s), and monthly follow-up for 6 months.
Number of subjects: 99
Study: 33762304

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33762322

Group type: EXPERIMENTAL
Intervention: Ad5 PSA/MUC-1/brachyury vaccine
Number of subjects: 18
Study: 33761533

Group type: EXPERIMENTAL
Intervention: Preoperative SARS-CoV-2 vaccination
Number of subjects: 0
Study: 33762734

Group type: EXPERIMENTAL
Intervention: Vaccine targeting mutant IDH1
Number of subjects: 0
Study: 33763199

Group type: EXPERIMENTAL
Intervention: Pramipexole Sustained Release (SR)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pramipexole Immediate Release (IR)
Number of subjects: 98
Study: 33763241

Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab (20 mg, IT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous + Intrathecal (IV+IT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 33763296

Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-matched control conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both 8-week and 16-week PP-MI interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related metrics (e.g. vital signs)
Number of subjects: 0
Study: 33763653

Group type: EXPERIMENTAL
Intervention: Protein/AS01
Number of subjects: 0
Study: 33763756

Group type: EXPERIMENTAL
Intervention: Emerging therapies including post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and combination therapies (AKT/PI3K/mTOR-inhibitors, immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, histone deacetylase inhibitors)
Number of subjects: 0
Study: 33763818

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 104
Study: 33764239

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/salm)
Number of subjects: 7787

Group type: COMPARATOR
Intervention: Budesonide/formoterol MART
Number of subjects: 7787
Study: 33764309

Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother program (text message program with 53 messages sent twice a day for the first 2 weeks and daily for weeks 3 through 6)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 140
Study: 33764552

Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency treatment
Number of subjects: 31
Study: 33764600

Group type: EXPERIMENTAL
Intervention: Sodium levofolinate (Na-Lev) in combination with 5-fluorouracil (5-FU) administered in a single 48-hour pump
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) with a 2-hour infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium levofolinate (Na-Lev)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium levofolinate (Ca-Lev)
Number of subjects: 60
Study: 33764808

Group type: EXPERIMENTAL
Intervention: Trastuzumab for centrally confirmed HER2+ mGC (central HER2+/local HER2+)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Trastuzumab for local HER2+ but central HER2- mGC
Number of subjects: 548
Study: 33764809

Group type: EXPERIMENTAL
Intervention: CD19.28ζ-CAR T cells
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fludarabine/cyclophosphamide-based lymphodepletion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT
Number of subjects: 50
Study: 33764812

Group type: EXPERIMENTAL
Intervention: HIV-care adherence assessment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Reasons for missing medications
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Healthcare payment method
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Awareness of HIV acquisition
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Relationship status
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Transition preparedness
Number of subjects: 252
Study: 33764991

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, banding, vertical banded gastroplasty)
Number of subjects: 4047

Group type: COMPARATOR
Intervention: Conventional obesity treatment (control group)
Number of subjects: 4047

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (surgery group)
Number of subjects: 4047

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study: 33765041

Group type: EXPERIMENTAL
Intervention: GlycA (mean plasma level 381 μmol/L)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 6602
Study: 33765092

Group type: EXPERIMENTAL
Intervention: ANN model (CUHAS-ROBUST application)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 487

Group type: COMPARATOR
Intervention: Decision Tree
Number of subjects: 487

Group type: COMPARATOR
Intervention: Random Forest
Number of subjects: 487

Group type: COMPARATOR
Intervention: Extreme Gradient Boost
Number of subjects: 487

Group type: COMPARATOR
Intervention: GeneXpert
Number of subjects: 487
Study: 33765161

Group type: EXPERIMENTAL
Intervention: BTI-RADS (Bone Tumor Imaging Reporting and Data System)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: BTI-RADS
Number of subjects: 230
Study: 33765164

Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (tyrosine kinase inhibitors or mTOR inhibitor)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (surveillance)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 432
Study: 33765419

Group type: EXPERIMENTAL
Intervention: Iptacopan (200 mg twice daily)
Number of subjects: 10
Study: 33765691

Group type: COMPARATOR
Intervention: Endothelin receptor antagonists (ERAs)
Number of subjects: 3322
Study: 33765926

Group type: EXPERIMENTAL
Intervention: HCCBloodTest (Epigenomics AG)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: NGS panel
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Combination of NGS panel with AFP (20 ng/mL)
Number of subjects: 163
Study: 33765964

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Core outcome and variables of interest set developed through a Delphi method
Number of subjects: 15000
Study: 33766028

Group type: EXPERIMENTAL
Intervention: Digital self-management interventions for chronic pain (specific details not provided)
Number of subjects: 12
Study: 33766036

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC) in patients with PAD and non-T2DM
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC) in patients with coexisting PAD and newly-diagnosed T2DM
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Cholesterol efflux capacity (CEC) in established T2DM patients
Number of subjects: 1002
Study: 33766089

Group type: EXPERIMENTAL
Intervention: SAVR with INSPIRIS RESILIA aortic valve
Number of subjects: 500
Study: 33766105

Group type: EXPERIMENTAL
Intervention: Theoretical Domains Framework used to identify barriers and enablers to screening and recruitment.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Identified barriers to screening.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Identified variability in roles and procedures.
Number of subjects: 15
Study: 33766146

Group type: EXPERIMENTAL
Intervention: Usual care plus an internet-based foot-ankle exercise program through SOPeD, 3 times per week for 12 weeks.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 14
Study: 33766254

Group type: EXPERIMENTAL
Intervention: Roche Diagnostics hs-cTn assay
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Abbott Diagnostics hs-cTn assay
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Siemens Diagnostics hs-cTn assay
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Management recommendations based on hs-cTn measurements
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Discharge recommendations
Number of subjects: 624
Study: 33766266

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33766502

Group type: EXPERIMENTAL
Intervention: Adaptive image-guided standard radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-escalated tumour boost radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33766817

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus CAPOX
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus CAPOX followed by camrelizumab plus apatinib
Number of subjects: 48
Study: 33766834

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 30
Study: 33766844

Group type: EXPERIMENTAL
Intervention: Community delivery of intermittent preventive treatment (C-IPTp) with sulfadoxine-pyrimethamine at each scheduled antenatal care (ANC) visit.
Number of subjects: 0
Study: 33766994

Group type: EXPERIMENTAL
Intervention: Psychiatric and cognitive symptoms in HD gene carriers
Number of subjects: 6316

Group type: EXPERIMENTAL
Intervention: Nonmotor symptoms
Number of subjects: 6316
Study: 33767059

Group type: EXPERIMENTAL
Intervention: APOL1 gene expression induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapeutic development inhibiting APOL1 synthesis or function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APOL1 variants
Number of subjects: 0
Study: 33767061

Group type: EXPERIMENTAL
Intervention: Early initiation of kidney replacement therapy (KRT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Delayed initiation of kidney replacement therapy (KRT)
Number of subjects: 4
Study: 33767093

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C5 inhibitors and daptomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF culture and PCR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct next-generation sequencing of CSF
Number of subjects: 0
Study: 33767162

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 0
Study: 33767648

Group type: EXPERIMENTAL
Intervention: iACTwithPain intervention (eight weekly self-management sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACT-only intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical TAU group
Number of subjects: 0
Study: 33767695

Group type: EXPERIMENTAL
Intervention: BCMA-7 × 19 CAR-T cells
Number of subjects: 2
Study: 33767713

Group type: EXPERIMENTAL
Intervention: Blood Interferon-α Levels
Number of subjects: 0
Study: 33768217

Group type: EXPERIMENTAL
Intervention: Increased uromodulin expression in overweight patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased uromodulin expression in older patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased uromodulin expression in patients with hypertension
Number of subjects: 0
Study: 33768227

Group type: EXPERIMENTAL
Intervention: Tdap vaccination (Boostrix, GSK Biologicals) during pregnancy
Number of subjects: 234

Group type: COMPARATOR
Intervention: Not applicable (unvaccinated control group)
Number of subjects: 234
Study: 33768419

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg Q3W
Number of subjects: 505

Group type: COMPARATOR
Intervention: Cemiplimab 3 mg/kg Q2W
Number of subjects: 505
Study: 33768426

Group type: EXPERIMENTAL
Intervention: PD with external biliary stent (PD-BS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard PD (ST-PD)
Number of subjects: 128
Study: 33768488

Group type: EXPERIMENTAL
Intervention: Teprotumumab (10 mg/kg initial intravenous infusion followed by 20 mg/kg every 3 weeks for 7 additional infusions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 0
Study: 33768637

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic and arachidonic acid supplementation at 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33768961

Group type: EXPERIMENTAL
Intervention: Physical Education (PE) lessons
Number of subjects: 10697

Group type: EXPERIMENTAL
Intervention: Fitness-focused lessons
Number of subjects: 10697

Group type: EXPERIMENTAL
Intervention: Girls-only lessons
Number of subjects: 10697

Group type: EXPERIMENTAL
Intervention: Field athletics
Number of subjects: 10697

Group type: EXPERIMENTAL
Intervention: Enjoyment of PE
Number of subjects: 10697
Study: 33769076

Group type: EXPERIMENTAL
Intervention: Ixazomib + lenalidomide + dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33769295

Group type: EXPERIMENTAL
Intervention: Therapeutic virtual reality human-human interface
Number of subjects: 109
Study: 33769300

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet intervention for 12 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Development and validation of a diabetes-specific quality of life questionnaire
Number of subjects: 12
Study: 33769355

Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg daily for 16 weeks
Number of subjects: 7
Study: 33769417

Group type: EXPERIMENTAL
Intervention: Xenon (Xe) inhalation for 24 hours after resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO), molecular hydrogen (H2), xenon (Xe), and argon (Ar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xenon (Xe) combined with targeted temperature management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xenon (Xe) and hydrogen (H2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled gases (Xe, Ar, NO, H2)
Number of subjects: 0
Study: 33769497

Group type: EXPERIMENTAL
Intervention: Apatinib, an anti-angiogenic tyrosine kinase inhibitor, administered once daily until disease progression, unmanageable toxicity, withdrawal, or death.
Number of subjects: 20
Study: 33769555

Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (including SMS, healthcare worker training, face-to-face counselling, electronic pillboxes, written materials, home blood pressure monitors)
Number of subjects: 25633

Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions
Number of subjects: 25633

Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (SMS and provider support)
Number of subjects: 25633

Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (SMS only)
Number of subjects: 25633
Study: 33769589

Group type: EXPERIMENTAL
Intervention: Clean intermittent self-catheterization (CISC)
Number of subjects: 25
Study: 33769768

Group type: EXPERIMENTAL
Intervention: Emergency department-based HIV screening strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current screening strategies
Number of subjects: 0
Study: 33769953

Group type: EXPERIMENTAL
Intervention: Patients with adrenal crises (AC)
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: PAI patients with AC
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: SAI patients with AC
Number of subjects: 2694
Study: 33770018

Group type: EXPERIMENTAL
Intervention: IOLMaster 700 (biometer A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ANTERION (biometer B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LENSTAR, LS900 (biometer C)
Number of subjects: 50